Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	253.73	88.21	139.26	203.13	127.44	80.93
Short-Term Investments	751.03	688.72	643.86	816.89	445.49	483.95
Cash & Short-Term Investments	1,005	776.93	783.12	1,020	572.93	564.88
Cash Growth	55.18%	-0.79%	-23.22%	78.04%	1.43%	-3.49%
Accounts Receivable	3.12	2.81	2.21	-	-	15.32
Other Receivables	-	1.1	0.3	7.28	-	-
Receivables	3.12	3.91	2.51	7.28	-	15.32
Inventory	26.43	19.08	8.49	-	-	7.33
Prepaid Expenses	39.89	33.92	38.66	36.94	15.89	24.18
Other Current Assets	-	-	-	-	47.86	-
Total Current Assets	1,074	833.84	832.77	1,064	636.68	611.7
Property, Plant & Equipment	57.66	69.79	88.12	104.23	116.07	126.11
Long-Term Investments	655.89	29.44	313.87	266.38	97.61	152.93
Other Long-Term Assets	4.06	4.06	3.96	2.9	2.6	-
Total Assets	1,792	937.12	1,239	1,438	852.95	890.74
Accounts Payable	17.14	9.78	18.62	16.7	17.72	21.9
Accrued Expenses	33.31	43.17	30.35	31.97	30.8	49.09
Current Portion of Leases	16.32	15.01	13.66	11.16	7.41	6.92
Current Income Taxes Payable	52.68	-	-	-	-	-
Current Unearned Revenue	-	-	-	-	-	10.93
Other Current Liabilities	-	-	-	-	38.46	4.05
Total Current Liabilities	119.45	67.96	62.63	59.83	94.39	92.89
Long-Term Leases	44.52	56.99	72	85.94	97.79	106.75
Long-Term Unearned Revenue	-	-	-	-	-	50.58
Other Long-Term Liabilities	1.16	1.16	3.28	-	261.27	-
Total Liabilities	165.12	126.1	137.9	145.76	453.45	250.21
Common Stock	0.07	0.07	0.07	0.07	0.07	0.07
Additional Paid-In Capital	2,478	2,437	2,386	2,334	2,243	2,156
Retained Earnings	-52.4	-822.65	-470.56	-238.76	-1,843	-1,516
Treasury Stock	-802.49	-802.49	-802.49	-802.49	-	-
Comprehensive Income & Other	3.42	-0.44	-12.54	-1.2	0.11	0.2
Shareholders' Equity	1,627	811.02	1,101	1,292	399.5	640.53
Total Liabilities & Equity	1,792	937.12	1,239	1,438	852.95	890.74
Total Debt	60.83	72	85.66	97.09	105.2	113.66
Net Cash (Debt)	1,600	734.37	1,011	1,189	565.34	604.14
Net Cash Growth	100.76%	-27.39%	-14.96%	110.37%	-6.42%	-24.99%
Net Cash Per Share	27.98	13.20	18.46	19.67	8.19	10.07
Filing Date Shares Outstanding	57.03	56.19	55.29	54.64	69.6	68.51
Total Common Shares Outstanding	57.02	55.95	55.04	54.33	69.29	68.4
Working Capital	954.74	765.88	770.14	1,004	542.28	518.82
Book Value Per Share	28.53	14.50	20.00	23.78	5.77	9.36
Tangible Book Value	1,627	811.02	1,101	1,292	399.5	640.53
Tangible Book Value Per Share	28.53	14.50	20.00	23.78	5.77	9.36
Machinery	-	29.73	35.12	33.8	35.49	32.52
Construction In Progress	-	0.61	0.66	7.37	4.11	7.18
Leasehold Improvements	-	37.28	37.28	32.73	32.57	23.88

Source: S&P Capital IQ. Standard template. Financial Sources.